32.71
+0.17(+0.52%)
Currency In USD
Address
110 East 59th Street
New York, NY 10022
United States of America
Phone
212 883 0200
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
June 16, 2020
| Name | Title | Pay | Year Born |
| Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | 0 | 1965 |
| Mr. George Wingate Lloyd | Executive Vice President of Investments & Chief Legal Officer | 1.26M | 1960 |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments | 1.26M | 1977 |
| Mr. Terrance P. Coyne | Executive Vice President & Chief Financial Officer | 1.26M | N/A |
| Mr. Christopher Hite | Vice Chairman & Executive Vice President | 1.26M | 1968 |
| Dr. James Folmar Reddoch Ph.D. | Executive Vice President of Investments & Chief Scientific Officer | 3.4M | 1971 |
| Ms. Kristin Stafford | Senior Vice President & Chief Accounting Officer | 0 | 1983 |
| Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel | 0 | N/A |
| Mr. Ashwin Pai M.D. | Executive Vice President of Investments | 0 | N/A |
| Mr. Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer | 0 | N/A |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.